Harvard Bioscience (NASDAQ:HBIO) Cut to “Hold” at Stonex Financial

Stonex Financial cut shares of Harvard Bioscience (NASDAQ:HBIO – Free Report) from a moderate buy rating to a hold rating in a research report sent to investors on Wednesday morning,Zacks reports.

HBIO has been the topic of a number of other research reports. Benchmark lifted their price objective on shares of Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research report on Wednesday, August 12th. Zacks Research started coverage on Harvard Bioscience in a research note on Tuesday, November 3rd. They set a “hold” rating on the stock. Weiss Ratings upgraded shares of Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, StoneX lowered shares of Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a research report on Wednesday. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Harvard Bioscience currently has a consensus rating of “Hold” and an average target price of $6.75.

Read Our Latest Stock Report on Harvard Bioscience

Harvard Bioscience Price Performance

Shares of HBIO opened at $9.39 on Wednesday. The company has a debt-to-equity ratio of 7.28, a quick ratio of 0.98 and a current ratio of 1.76. The business has a fifty day moving average of $8.34 and a 200 day moving average of $6.58. Harvard Bioscience has a 52-week low of $4.00 and a 52-week high of $10.20.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. The company had revenue of $22.20 million during the quarter, compared to analysts’ expectations of $21.80 million. On average, research analysts predict that Harvard Bioscience will post -2.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Harvard Bioscience stock. Meros Investment Management LP purchased a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned 4.02% of Harvard Bioscience as of its most recent filing with the SEC. 80.87% of the stock is owned by institutional investors.

About Harvard Bioscience

(Get Free Report)

Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.

Read More

Analyst Recommendations for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.